Veröffentlichungswege

Kozakov, Kostiantyn , Philipp, Alois, Foltan, Maik , Heller, Anton, Turtsevich, Dzmitry, Schach, Christian , Ellmauer, Peter‐Paul, Petermichl, Walter , Flörchinger, Bernhard, Schmid, Christof, Schopka, Simon und Provaznik, Zdenek (2025) Inflammatory Cytokines as Early Predictors of Weaning Failure From Extracorporeal Life Support. Artificial Organs.

Roth, Nastasia , Heidel, Carolin, Xu, Congde, Hubauer, Ute, Wallner, Stefan, Meindl, Christine, Holzamer, Andreas, Hilker, Michael, Creutzenberg, Marcus, Sossalla, Samuel, Maier, Lars, Jungbauer, Carsten und Debl, Kurt (2023) Restoration of von Willebrand factor after transcatheter aortic valve replacement—A possible cause for posttranscatheter aortic valve replacement thrombocytopenia? Catheterization and Cardiovascular Interventions.

Holzamer, Andreas , Bedogni, Francesco, van Wyk, Pieter, Barwad, Parag, Protasiewicz, Marcin, Ielasi, Alfonso, Nombela‐Franco, Luis, Seidler, Tim und Hilker, Michael (2023) Performance of the 32 mm Myval transcatheter heart valve for treatment of aortic stenosis in patients with extremely large aortic annuli in real‐world scenario: First global, multicenter experience. Catheterization and Cardiovascular Interventions.

Lingel, Maximilian P., Haus, Moritz, Paschke, Lukas, Foltan, Maik , Lubnow, Matthias , Gruber, Michael , Krenkel, Lars und Lehle, Karla (2023) Clinical relevance of cell‐free DNA during venovenous extracorporeal membrane oxygenation. Artificial Organs.

Provaznik, Zdenek , Philipp, Alois, Müller, Thomas , Kostiantyn, Kozakov, Lunz, Dirk, Schmid, Christof und Floerchinger, Bernhard (2022) Outcome after veno‐venous extracorporeal membrane oxygenation in elderly compared to younger patients: A 14‐year retrospective observational study. Artificial Organs, S. 1-9.

Provaznik, Zdenek , Philipp, Alois, Müller, Thomas , Kostiantyn, Kozakov, Lunz, Dirk, Schmid, Christof und Floerchinger, Bernhard (2022) Outcome after veno‐arterial extracorporeal membrane oxygenation in elderly patients: A 14‐year single‐center experience. Artificial Organs 47 (4), S. 740-748.

Elsner, Felix, Hoffmann, Martin, Fahrioglu‐Yamaci, Rezan, Czyz, Zbigniew, Feliciello, Giancarlo, Mederer, Tobias , Polzer, Bernhard, Treitschke, Steffi, Rümmele, Petra, Weber, Florian , Wiesinger, Hellmuth, Robold, Tobias, Sziklavari, Zsolt, Sienel, Wulf, Hofmann, Hans‐Stefan und Klein, Christoph A. (2022) Disseminated cancer cells detected by immunocytology in lymph nodes of NSCLC patients are highly prognostic and undergo parallel molecular evolution. The Journal of Pathology 258 (3), S. 250-263.

Kozakov, Kostiantyn , Philipp, Alois, Lunz, Dirk, Lubnow, Matthias, Provaznik, Zdenek, Keyser, Andreas, Rupprecht, Leopold, Schmid, Christof und Schopka, Simon (2022) Multi‐organ dysfunction syndrome in patients undergoing extracorporeal life support. Artificial Organs 46 (9), S. 1912-1922.

Lehle, Karla , Philipp, Alois, Foltan, Maik, Schettler, Frank, Ritzka, Markus , Müller, Thomas und Lubnow, Matthias (2022) Coagulation abnormalities in patients with COVID‐19 on venovenous ECLS increased risk for technical complications and support times but had no impact on survival. Artificial Organs, S. 1-13.

Zeller, Judith , Hubauer, Ute, Schober, Andreas , Schober, Alexander, Keyser, Andreas , Fredersdorf, Sabine, Uecer, Ekrem , Maier, Lars S. und Jungbauer, Carsten G. (2021) Heart failure with recovered ejection fraction (HFrecEF): A new entity with improved cardiac outcome. Pacing and Clinical Electrophysiology 44, S. 2015-2023.

Allgaier, Raphael , Strack, Christina, Wallner, Stefan, Hubauer, Ute, Uecer, Ekrem, Lehn, Petra, Keyser, Andreas, Luchner, Andreas, Maier, Lars und Jungbauer, Carsten (2020) N-acetyl-b-D-glucosaminidase: A potential cardiorenal biomarker with a relevant impact on ICD shock therapies and mortality. Nephrology 25 (12), S. 888-896.

Lebek, Simon, Tafelmeier, Maria, Messmann, Rebecca, Provaznik, Zdenek, Schmid, Christof, Maier, Lars S., Birner, Christoph, Arzt, Michael und Wagner, Stefan (2020) Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease. European Journal of Heart Failure 22, S. 2248-2257.